Not recruitingISRCTN61794329
Does oral N-acetyl-cysteine (NAC) improve schizophrenia symptoms?
Research studySwitzerland + United States
Understand this study
- Listed locations
- Switzerland · United States
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateNot clearly listed
- Recruitment status
- Not recruiting
- Enrollment listed in the registry
- Not clearly listed
- Sponsor
- Swiss National Science Foundation (Fonds National Suisse de la Recherche Scientifique [SNSF]) (Switzerland)
- Sponsor type
- Non-profit organization
- Study type
- Other
- Intervention type
- Other / unclear
- Study phase
- Not clearly listed
- Locations
- United States, Switzerland
- Age range
- Not clearly listed
- Official registry ID
- ISRCTN61794329
- Official title
Show the full official title
Does oral N-acetyl-cysteine (NAC) improve schizophrenia symptoms?
Recruitment & locations
Not recruitingThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Switzerland · United States
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Swiss National Science Foundation (Fonds National Suisse de la Recherche Scientifique [SNSF]) (Switzerland).
Is this study still recruiting?
The registry lists this study as not recruiting.
Want to explore more studies?
Explore studiesRelated studies
A phase III randomised, double-blind, active comparator-controlled clinical trial to study the safety and efficacy of lurasidone in subjects with schizophrenia (PEARL 3 extension study)
A phase three randomised, placebo-controlled, clinical trial to study the safety and efficacy of three doses of lurasidone hydrochloride (HCl) in acutely psychotic patients with schizophrenia